What is Lyfnua used for?

Lyfnua is indicated for Refractory chronic cough.

Lyfnua is developed by Msd K.K..

What development phase is Lyfnua in?

Lyfnua is FDA-approved (marketed).

What is the generic name of Lyfnua?

GEFAPIXANT CITRATE is the generic (nonproprietary) name of Lyfnua.

Last reviewed 2026-05-14 · How we verify

Lyfnua (GEFAPIXANT CITRATE)

Msd K.K. · FDA-approved approved Small molecule Quality 17/100

At a glance

Generic name	GEFAPIXANT CITRATE
Sponsor	Msd K.K.
Target	P2X purinoceptor 3
Modality	Small molecule
Therapeutic area	Pain
Phase	FDA-approved
First approval	2023

Approved indications

Refractory chronic cough

Common side effects

No common side effects on file.

Key clinical trials

The Real-world Treatment Satisfaction by Gefapixiant in RCC (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Lyfnua CI brief — competitive landscape report
Lyfnua updates RSS · CI watch RSS
Msd K.K. portfolio CI